Prothena Announces Bristol Myers Squibb Opt-in for Worldwide Rights of PRX005, a Novel Anti-MTBR-Tau

Prothena to receive $55 million from Bristol Myers Squibb for exclusive worldwide license to PRX005, building on exclusive U.S. license which was optioned in June 2021Bristol Myers Squibb will be responsible for development, manufacturing, and commercialization going forward DUBLIN--(BUSINESS WIRE)--$PRTA #prothena-...

Related Keywords

,Michael Bachner ,Richard Hargreaves ,Bristol Myers Squibb ,Prothena Corporation ,Corporate Communications ,Nasdaq ,Company On Twitter Prothenacorp ,Exchange Commission ,Myers Squibb ,Gene Kinney ,Chief Executive Officer ,Senior Vice President ,Neuroscience Thematic Research ,Quarterly Report ,Investor Contact ,Senior Director ,